NEW YORK (GenomeWeb) – Premaitha Health and Coastal Genomics have signed an agreement to develop technologies for clinical DNA sequencing tests, Premaitha said today.
Under the agreement, Coastal Genomics, based in Vancouver, and Premaitha, located in Manchester, UK, plan to develop technologies "to enhance aspects of Premaitha Health's in vitro diagnostic product portfolio" for reproductive health and other applications.
Specifically, Costal Genomics plans to "deliver a customized solution for Premaitha that can be widely deployed for DNA sequencing," said Matthew Nesbitt, president of Coastal Genomics, in a statement.
Coastal Genomics provides automated solutions for sample preparation across medical diagnostics, while Premaitha focuses on noninvasive prenatal testing.